Posted by Michael Wonder on 23 Feb 2023
Arcutis submits roflumilast 0.3% topical foam new drug application to the FDA for the treatment of seborrheic dermatitis in adults and adolescents
21 February 2023 - In a pivotal Phase 3 trial, 80% of individuals treated with roflumilast foam achieved IGA success at Week 8.
Arcutis Biotherapeutics today announced the submission of a new drug application to the US FDA for roflumilast 0.3% topical foam for the treatment of moderate to severe seborrheic dermatitis in adults and adolescents.
